Shirt a Phobia

Sample Page

Relacorilant, sold under the brand name Lifyorli, is an anti-cancer medication used for the treatment of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.[1] Relacorilant is a glucocorticoid receptor antagonist.[1]

The most common adverse reactions include decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash, and decreased appetite.[2]

Relacorilant was approved for medical use in the United States in March 2026.[2][3]

Medical uses

Relacorilant is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.[1]

Adverse effects

The US prescribing information includes a contraindication for people who require corticosteroids for a lifesaving indication as well as warnings and precautions for neutropenia and severe infections, adrenal insufficiency, exacerbation of conditions treated with glucocorticoids, and embryo-fetal toxicity.[2] The most common adverse reactions include decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash, and decreased appetite.[2]

History

Efficacy was evaluated in ROSELLA (NCT05257408), a multicenter, open-label, trial in 381 participants with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.[2] Participants were permitted to receive up to three prior lines of systemic therapy and prior bevacizumab was required.[2] The trial excluded participants who required chronic or frequent use of glucocorticoids.[2] Participants were randomized (1:1) to receive relacorilant in combination with nab-paclitaxel or nab-paclitaxel alone.[2]

References

  1. ^ a b c d “Lifyorli- relacorilant kit”. DailyMed. 26 March 2026. Retrieved 1 April 2026.
  2. ^ a b c d e f g h “FDA approves relacorilant with nab-paclitaxel for platinum-resistant”. U.S. Food and Drug Administration (FDA). 25 March 2026. Retrieved 5 April 2026. Public Domain This article incorporates text from this source, which is in the public domain.
  3. ^ Kansteiner F (25 March 2026). “Corcept’s lead drug bounces back from FDA snub with different approval as Lifyorli in ovarian cancer”. Fierce Pharma. Retrieved 26 March 2026.
  • Clinical trial number NCT05257408 for “Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer” at ClinicalTrials.gov